This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform.

In vivo CAR-T therapy is emerging as a transformative approach to overcome the limitations of traditional ex vivo manufacturing. Circular RNA (circRNA) offers unique advantages—prolonged expression, reduced immunogenicity, and enhanced reprogramming efficiency—making it an ideal tool to enable in vivo CAR-T applications. In this webinar, we will discuss how circRNA addresses key challenges in safety, efficacy, and scalability, and share insights from YXgene’s proprietary circRNA technology platform that supports translational research and clinical development.

Learning Objectives:

1. Understand the key challenges of in vivo CAR-T therapy and how circular RNA technology can address limitations in safety, efficacy, and manufacturing scalability.

2. Explore the unique properties of circular RNA—including prolonged expression, reduced immunogenicity, and high reprogramming efficiency—that make it an enabling tool for next-generation CAR-T development.

3. Gain insights into practical applications of circRNA platforms in supporting translational research, clinical development, and future collaborations in the in vivo CAR-T field.